Alcon has entered into the surgical glaucoma market by acquiring Optonol, a manufacturer and marketer of novel minature surgical implants used to reduce IOP.
Alcon has entered into the surgical glaucoma market by acquiring Optonol, a manufacturer and marketer of novel minature surgical implants used to reduce IOP.
The move will enable Alcon to acquire the Ex-PRESS Mini Glaucoma Shunt to complement its pharmaceutical products that lower IOP. The acquisition of Optonol is part of our strategy to bolster organic growth with targeted investments in key therapeutic areas that have the potential to contribute in both the near and long term, said Kevin Buehler, Alcon's president and chief executive officer. Because the product is already approved in the United States and other major markets it will begin contributing commercially in 2010.
